Three May Be Better Than Two: A Proposal for Metformin Addition to PI3K/Akt Inhibitor-antiandrogen Combination in Castration-resistant Prostate Cancer
Three May Be Better Than Two: A Proposal for Metformin Addition to PI3K/Akt Inhibitor-antiandrogen Combination in Castration-resistant Prostate Cancer
复制标题
DOI：
10.7759/cureus.3403
复制
发表时间：
2018-10-01
影响因子：
1.2
通讯作者：
Delma, Mohamed Islam
中科院分区：
文献类型：
--
作者：
Delma, Mohamed Islam
前列腺癌是一种常见的恶性肿瘤。去势抵抗性前列腺癌（CRPC）是一种预后不良的形式，在对一线雄激素剥夺治疗抵抗时发展。目前正在进行深入的研究，以找到这种难治性状态的有效治疗方法。实际上，PI 3 K/Akt抑制剂与新一代抗雄激素的组合是最有前途的治疗方案之一，尽管尚未达到最佳水平。本文综述了美托洛尔对前列腺癌的作用，特别是其与抗雄激素和/或PI 3 K/Akt抑制剂共有的治疗靶点。由此，将推导出通过在CRPC中添加二甲双胍优化PI 3 K/Akt-抗雄激素双重阻断的假设。
Prostate cancer is a prevalent malignant disease. Castration-resistant prostate cancer (CRPC) is a poor prognosis form that develops upon resistance to first-line androgen deprivation therapy. Intensive research is ongoing to find efficient therapeutics for this refractory state. Actually, the combination of PI3K/Akt inhibitors with new-generation antiandrogens is among the most promising therapeutic schemes, although not yet at the optimal level. Metformin effects on prostate cancer, notably its therapeutic targets shared with antiandrogens and/or PI3K/Akt inhibitors, are reviewed in this article. From that, the hypothesis of PI3K/Akt-antiandrogens dual blockade optimization by metformin addition in CRPC will be deduced.